Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — 9M 2026 Earnings Presentation
21 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Oct 22, 2026
Slide 1: Jamjoom Pharma Earnings Presentation 9M 2026
Jamjoom Pharma Earnings Presentation 9M 2026 Jamjoom Earnings Presentation 22/10/2026
Slide 2: Disclaimer
IMPORTANT NOTICE Disclaimer This presentation has been prepared solely for use as an investor presentation for This presentation has not been approved by any competent regulatory authority. Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by Neither this presentation nor anyt
Slide 3: Core Business Highlights
Core Business Highlights Jamjoom Earnings Presentation 22/10/2026
Slide 4: Delivering profitability in a tough environment and raising returns to shareholders
Delivering profitability in a tough environment and raising returns to shareholders Revenue EBITDA1 Net Profit 1,281.4 477.0 416.1 +7.1% YoY +7.2% YoY +5.1% YoY mn mn 37.2% Margin mn 32.5% NPM EPS: 5.94 Growth since 9M 20234 Growth since 9M 20234 Growth since 9M 20234 Dividend ( Per Share)
Slide 5: Growth came from all core therapeutic areas and key markets
BUSINESS AND STRATEGY HIGHLIGHTS Growth came from all core therapeutic areas and key markets Revenue Contribution by Country, YoY ( mn) Revenue Contribution by Therapeutic Area, YoY ( mn) +7% +7% 17 16 7 3 1,281 42 1,196 30 0.8 1,281 25 6 (17) Market share UAE retail outperformance Strong Q3 gains
Slide 6: Outperforming the market in a challenging environment
BUSINESS AND STRATEGY HIGHLIGHTS Outperforming the market in a challenging environment YTD MAT Key Takeaways Jan–Aug 2026 MAT Aug 2026 Double-digit YTD growth in a flat market reinforces Sales growth vs prior year (PPG) Sales growth vs prior year (PPG) JP’s market share gain +10.2pp +14.7pp i Weaker
Slide 7: JP grew 27.5% YTD in the UAE, 15.6pp ahead of the market
BUSINESS AND STRATEGY HIGHLIGHTS JP grew 27.5% YTD in the UAE, 15.6pp ahead of the market YTD MAT Jan–Aug 2026 MAT Aug 2026 Sales growth vs prior year (PPG) Sales growth vs prior year (PPG) +15.6pp +9.2pp +27.5% +22.6% +13.4% +11.9% UAE market Jamjoom Pharma UAE market Jamjoom Pharma JP PVT sales Ma
Slide 8: Progress on our six priorities for H2 2026
BUSINESS AND STRATEGY HIGHLIGHTS Progress on our six priorities for H2 2026 01 02 03 Sustain market outperformance KAEC acquisition Vaccine & Biologics JV across key therapeutic areas and markets CAGR ahead of market¹: KSA +5.0pp, UAE Transition completed successfully and ramp-up Detailed plans to b
Slide 9: Strategic Growth Levers
Strategic Growth Levers Jamjoom Earnings Presentation 22/10/2026
Slide 10: 62 product pipeline & 27 Under-License agreements supports 7–9 new launches a year
STRATEGIC GROWTH LEVERS 62 product pipeline & 27 Under-License agreements supports 7–9 new launches a year 7–9 new launches/year planned over the next five years (contributing c.40–50% of revenue growth) In-house: 4–5 brands. In-licensed: 3–4 brands, including biosimilars New-product pipeline (62 Pr
Slide 11: KAEC acquisition adds approved capacity with an experienced team
STRATEGIC GROWTH LEVERS KAEC acquisition adds approved capacity with an experienced team at a fraction of the cost All regulatory approvals secured 40+ employees with MNC experience ANNUAL CAPACITY GREENFIELD COST Accelerated returns expected from 18M ~2.5× Q4 2027 onwards Units per year, with signi
Slide 12: Vaccines & Biologics Strategic Alliance gives JP a phased entry
STRATEGIC GROWTH LEVERS Vaccines & Biologics Strategic Alliance gives JP a phased entry into vaccines and biologics DEVELOPMENT ROADMAP Potential secondary packaging could bridge the gap to full operations End 2026 – Q1 2027 2027–2028 2028–2030+ Planning & Capital Sourcing & Registration Constructio
Slide 13: JP is investing through the cycle to capture growth as markets recover
OUTLOOK JP is investing through the cycle to capture growth as markets recover READINESS KAEC facility Main-site expansion Ready to lead the Acquiring an approved site adds 18M units To improve productivity at the main site to recovery of annual capacity, with returns expected support rising demand
Slide 14: Financial Highlights
Financial Highlights Jamjoom Earnings Presentation 22/10/2026
Slide 15: 3Q 2026 net profit rose 3.3%, with gross profit up 6.9%
FINANCIAL HIGHLIGHTS 3Q 2026 net profit rose 3.3%, with gross profit up 6.9% Revenue ( mn) EBITDA ( mn) ━━ +4% YoY growth +6% YoY growth 342 355 124 131 EBITDA Margin 36.3% → 37.1% Growth led by KSA and Iraq Outpaced revenue growth, as gross margin gains more than offset higher operating expenses.
Slide 16: Cost of revenue rose only 2% as raw material savings offset mix and plant costs
FINANCIAL HIGHLIGHTS Cost of revenue rose only 2% as raw material savings offset mix and plant costs Total Cost Of Revenue Movement YoY (mn) Direct Production Cost Per Unit Sold () Unit cost declined by 0.2, driven by a +2% Slight decrease was continued favorable 3.3 driven by changes 3 2 454 3.
Slide 17: Balancing Growth and Working Capital Efficiency
FINANCIAL HIGHLIGHTS Balancing Growth and Working Capital Efficiency Cash Conversion Cycle (Days) +2% Cash conversion cycle increased by 2.0% YoY to 302 days, compared to 296 days in 9M 2025, reflecting higher receivable days, partially offset by improved inventory and 296 302 extended payable days.
Slide 18: Putting our money where it matters: five investment priorities
CAPITAL ALLOCATION Putting our money where it matters: five investment priorities 01 02 03 04 05 Portfolio expansion Portfolio acquisitions Vaccines & Biologics KAEC ramp-up & Expansionary CAPEX JV expansion R&D spending and Exploring acquisitions Phased investment in Ramp to full utilization Additi
Slide 19: Outlook and Guidance
Outlook and Guidance Jamjoom Earnings Presentation 22/10/2026
Slide 20: Updated FY 2026 Guidance
OUTLOOK AND GUIDANCE Updated FY 2026 Guidance Updated Guidance (FY2026 Only) FY 2027 guidance to follow with FY 2026 results REVISED MAINTAINED MAINTAINED MAINTAINED Revenue growth EBITDA margin CAPEX / Revenue Dividend (semi-annual) 7–9% 33–35% 6–9% 50–60% FY 2026 payout Revised down from the 10–12
Slide 21: Thank You
Thank You I N V E S T O R R E L AT I O N S [email protected] Jamjoom Earnings Presentation 22/10/2026
Jamjoom Pharmaceuticals Factory — 9M 2026 Earnings Presentation on 6ix